In a significant clinical analysis, 60% of people treated with Enhertu were alive at the time of data analysis. This figure provides a clear indication of patient outcomes in a specific study.
Understanding Enhertu's Efficacy
Enhertu (trastuzumab deruxtecan-nxki) is a targeted therapy used in the treatment of certain types of cancer, particularly HER2-low metastatic breast cancer. The survival rate mentioned reflects the proportion of patients who were still alive at a defined point during the clinical evaluation, providing crucial insights into the drug's effectiveness compared to conventional treatments.
Comparative Survival Data
To provide context, the survival rate for Enhertu can be compared with that of traditional chemotherapy in the same study:
| Treatment | Percentage Alive at Data Analysis | Number Alive (Total Treated) |
|---|---|---|
| Enhertu | 60% | 224 of 373 |
| Chemotherapy | 51% | 94 of 184 |
This comparison highlights that Enhertu demonstrated a higher percentage of patients alive at the time of data analysis compared to chemotherapy in this specific patient group.
Implications for Patients
The 60% survival rate at the time of data analysis indicates a meaningful benefit for patients treated with Enhertu. This type of data helps healthcare professionals and patients understand the potential effectiveness of the treatment in improving outcomes. It's important to discuss individual circumstances and treatment plans with a qualified healthcare provider.
For more information on Enhertu and its clinical applications, you may visit the official Enhertu website.
